Sun Pharmaceutical is currently trading at Rs. 1496.95, up by 2.20 points or 0.15% from its previous closing of Rs. 1494.75 on the BSE.
The scrip opened at Rs. 1499.95 and has touched a high and low of Rs. 1502.65 and Rs. 1492.55 respectively. So far 7890 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 986.40 on 27-Jun-2023.
Last one week high and low of the scrip stood at Rs. 1530.00 and Rs. 1461.40 respectively. The current market cap of the company is Rs. 358820.54 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.54% and 8.97% respectively.
Sun Pharmaceutical Industries (together with its subsidiaries and/or associated companies) has successfully completed the merger of Taro Pharmaceutical Industries (Taro) with its subsidiary. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-owned by Sun Pharma. Sun Pharma has been the majority shareholder of Taro since 2010.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: